Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Aerobic glycolysis in Schizophrenia: Developmental rescue or energetic breakdown?

Molecular Psychiatry (2026)Cite this article

Subjects

Abstract

Aerobic glycolysis (AG) refers to the preferential use of glucose through glycolysis and not oxidative phosphorylation (OxPhos) despite the presence of oxygen. Originally described in cancer cells as the Warburg effect, AG is now recognized as a broader physiological mechanism extending beyond cancer biology. This process is less efficient than OxPhos in terms of ATP yield, but supports biosynthesis, neural plasticity, oxidative stress reduction, and synaptogenesis under metabolically demanding conditions. Building on this physiological role and current findings, we propose that in schizophrenia (SZ), AG remains elevated in adulthood, likely reflecting a compensatory response to reduced brain biomass and mitochondrial dysfunction. Neuroimaging, spectroscopy, and postmortem studies link the presence of AG in the brain to impaired OxPhos, reductive stress and defective neuron-glia coupling. Oligodendrocyte dysfunction and white matter damage also additionally compromise energy homeostasis and connectivity. Though AG supports repair, its persistent activation may destabilize synaptic structures and function. This Perspective proposes that AG in SZ represents a mismatch between developmental demands and adult metabolic function, compensatory in early stages but ultimately (mal)adaptive. Understanding when, where and why AG persists may reveal new entry points for restoring energetic balance in vulnerable brain circuits.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9:148–63.

    Article  CAS  Google Scholar 

  2. Maurer I, Zierz S, Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res. 2001;48:125–36.

    Article  CAS  PubMed  Google Scholar 

  3. Campbell IH, Campbell H. The metabolic overdrive hypothesis: hyperglycolysis and glutaminolysis in bipolar mania. Mol Psychiatry. 2024;29:1521–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bergsneider M, Hovda DA, Shalmon E, Kelly DF, Vespa PM, Martin NA, et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J Neurosurg. 1997;86:241–51.

    Article  CAS  PubMed  Google Scholar 

  5. Dean B, Thomas N, Scarr E, Udawela M. Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia. Transl Psychiatry. 2016;6:e949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim SY, Cohen BM, Chen X, Lukas SE, Shinn AK, Yuksel AC, et al. Redox dysregulation in schizophrenia revealed by in vivo NAD+/NADH measurement. Schizophr Bull. 2017;43:197–204.

    Article  PubMed  Google Scholar 

  7. Chouinard VA, Kim SY, Valeri L, Yuksel C, Ryan KP, Chouinard G, et al. Brain bioenergetics and redox state measured by (31)P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders. Schizophr Res. 2017;187:11–16.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science. 2001;293:510–4.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang Q, Piston DW, Goodman RH. Regulation of corepressor function by nuclear NADH. Science. 2002;295:1895–7.

    Article  CAS  PubMed  Google Scholar 

  10. Stein A, Zhu C, Du F, Öngür D. Magnetic resonance spectroscopy studies of brain energy metabolism in schizophrenia: Progression from prodrome to chronic psychosis. Curr Psychiatry Rep. 2023;25:659–69.

    Article  PubMed  Google Scholar 

  11. Bauernfeind AL, Barks SK, Duka T, Grossman LI, Hof PR, Sherwood CC. Aerobic glycolysis in the primate brain: reconsidering the implications for growth and maintenance. Brain Struct Funct. 2014;219:1149–67.

    Article  CAS  PubMed  Google Scholar 

  12. Goyal MS, Blazey T, Metcalf NV, McAvoy MP, Strain JF, Rahmani M, et al. Brain aerobic glycolysis and resilience in Alzheimer disease. Proc Natl Acad Sci USA. 2023;120:e2212256120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dyrstad SE, Lotsberg ML, Tan TZ, Pettersen IKN, Hjellbrekke S, Tusubira D, et al. Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with EGFR TKI and Ionizing radiation increases therapeutic effect in non-small cell lung cancer cells. Cancers (Basel). 2021;13:941.

    Article  CAS  PubMed  Google Scholar 

  14. Stacpoole PW. Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J Natl Cancer Inst. 2017;109:https://doi.org/10.1093/jnci/djx071.

  15. Pettit FH, Pelley JW, Reed LJ. Regulation of pyruvate dehydrogenase kinase and phosphatase by acetyl-CoA/CoA and NADH/NAD ratios. Biochem Biophys Res Commun. 1975;65:575–82.

    Article  CAS  PubMed  Google Scholar 

  16. Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, Do BT, et al. Increased demand for NAD(+) relative to ATP drives aerobic glycolysis. Mol Cell. 2021;81:691–707.e6.

    Article  CAS  PubMed  Google Scholar 

  17. Wang Y, Stancliffe E, Fowle-Grider R, Wang R, Wang C, Schwaiger-Haber M, et al. Saturation of the mitochondrial NADH shuttles drives aerobic glycolysis in proliferating cells. Mol Cell. 2022;82:3270–83.e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Roberts RC. Mitochondrial dysfunction in schizophrenia: With a focus on postmortem studies. Mitochondrion. 2021;56:91–101.

    Article  CAS  PubMed  Google Scholar 

  19. Juaristi I, Llorente-Folch I, Satrústegui J, Del Arco A. Extracellular ATP and glutamate drive pyruvate production and energy demand to regulate mitochondrial respiration in astrocytes. Glia. 2019;67:759–74.

    Article  PubMed  Google Scholar 

  20. Dogan AE, Yuksel C, Du F, Chouinard VA, Öngür D. Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies. Neuropsychopharmacology. 2018;43:1681–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rowland LM, Pradhan S, Korenic S, Wijtenburg SA, Hong LE, Edden RA, et al. Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study. Transl Psychiatry. 2016;6:e967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Colucci ACM, Tassinari ID, Loss EDS, de Fraga LS. History and function of the lactate receptor GPR81/HCAR1 in the brain: A putative therapeutic target for the treatment of cerebral ischemia. Neuroscience. 2023;526:144–63.

    Article  CAS  PubMed  Google Scholar 

  23. Horvat A, Zorec R, Vardjan N. Lactate as an Astroglial signal augmenting aerobic glycolysis and lipid metabolism. Front Physiol. 2021;12:735532.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Magistretti PJ, Allaman I. Lactate in the brain: from metabolic endproduct to signalling molecule. Nat Rev Neurosci. 2018;19:235–49.

    Article  CAS  PubMed  Google Scholar 

  25. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell. 2011;144:810–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Davalieva K, Maleva Kostovska I, Dwork AJ. Proteomics research in schizophrenia. Front Cell Neurosci. 2016;10:18.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Martins-de-Souza D. Proteomics as a tool for understanding schizophrenia. Clin Psychopharmacol Neurosci. 2011;9:95–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sahay S, Pulvender P, Rami Reddy MVSR, McCullumsmith RE, O’Donovan SM. Metabolic insights into neuropsychiatric illnesses and ketogenic therapies: A transcriptomic view. Int J Mol Sci. 2024;25:8266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Stone WS, Faraone SV, Su J, Tarbox SI, Van Eerdewegh P, Tsuang MT. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet B Neuropsychiatr Genet. 2004;127B:5–10.

    Article  PubMed  Google Scholar 

  30. Chugani HT. A critical period of brain development: studies of cerebral glucose utilization with PET. Prev Med. 1998;27:184–8.

    Article  CAS  PubMed  Google Scholar 

  31. Goyal MS, Hawrylycz M, Miller JA, Snyder AZ, Raichle ME. Aerobic glycolysis in the human brain is associated with development and neotenous gene expression. Cell Metab. 2014;19:4957.

    Article  Google Scholar 

  32. Dienel GA. Brain Glucose Metabolism: Integration of Energetics with Function. Physiol Rev. 2019;99:949–1045.

    Article  CAS  PubMed  Google Scholar 

  33. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME. Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA. 2010;107:17757–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Goyal MS, Vlassenko AG, Blazey TM, Su Y, Couture LE, Durbin TJ, et al. Loss of brain aerobic glycolysis in normal human aging. Cell Metab. 2017;26:353–60.e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1982;2:163–71.

    Article  CAS  PubMed  Google Scholar 

  36. Dastur DK. Cerebral blood flow and metabolism in normal human aging, pathological aging, and senile dementia. J Cereb Blood Flow Metab. 1985;5:1–9.

    Article  CAS  PubMed  Google Scholar 

  37. Townsend L, Pillinger T, Selvaggi P, Veronese M, Turkheimer F, Howes O. Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of (18)FDG-PET studies in schizophrenia. Psychol Med. 2023;53:4880–97.

    Article  PubMed  Google Scholar 

  38. Chan ST, McCarthy MJ, Vawter MP. Psychiatric drugs impact mitochondrial function in brain and other tissues. Schizophr Res. 2020;217:136–47.

    Article  PubMed  Google Scholar 

  39. Au E, Panganiban KJ, Wu S, Sun K, Humber B, Remington G, et al. Antipsychotic-Induced dysregulation of glucose metabolism through the central nervous system: A scoping review of animal models. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025;10:244–57.

    PubMed  Google Scholar 

  40. Castellani LN, Pereira S, Kowalchuk C, Asgariroozbehani R, Singh R, Wu S, et al. Antipsychotics impair regulation of glucose metabolism by central glucose. Mol Psychiatry. 2022;27:4741–53.

    Article  CAS  PubMed  Google Scholar 

  41. Rocha A, Bellaver B, Souza DG, Schu G, Fontana IC, Venturin GT, et al. Clozapine induces astrocyte-dependent FDG-PET hypometabolism. Eur J Nucl Med Mol Imaging. 2022;49:2251–64.

    Article  CAS  PubMed  Google Scholar 

  42. Steiner J, Martins-de-Souza D, Schiltz K, Sarnyai Z, Westphal S, Isermann B, et al. Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. Front Cell Neurosci. 2014;8:384.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Zala D, Hinckelmann MV, Yu H, Lyra da Cunha MM, Liot G, Cordelières FP, et al. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell. 2013;152:479–91.

    Article  CAS  PubMed  Google Scholar 

  44. Altman DI, Perlman JM, Volpe JJ, Powers WJ. Cerebral oxygen metabolism in newborns. Pediatrics. 1993;92:99–104.

    Article  CAS  PubMed  Google Scholar 

  45. Powers WJ, Rosenbaum JL, Dence CS, Markham J, Videen TO. Cerebral glucose transport and metabolism in preterm human infants. J Cereb Blood Flow Metab. 1998;18:632–8.

    Article  CAS  PubMed  Google Scholar 

  46. DiNuzzo M, Dienel GA, Behar KL, Petroff OA, Benveniste H, Hyder F, et al. Neurovascular coupling is optimized to compensate for the increase in proton production from nonoxidative glycolysis and glycogenolysis during brain activation and maintain homeostasis of pH, pCO(2), and pO(2). J Neurochem. 2024;168:632–62.

    Article  CAS  PubMed  Google Scholar 

  47. Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: Still emerging. Cell Metab. 2022;34:355–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Chandel NS. Lipid metabolism. Cold Spring Harb Perspect Biol. 2021;13:a040576.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Brier MR, Blazey T, Raichle ME, Morris JC, Benzinger TLS, Vlassenko AG, et al. Increased white matter glycolysis in humans with cerebral small vessel disease. Nat Aging. 2022;2:991–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Traxler L, Herdy JR, Stefanoni D, Eichhorner S, Pelucchi S, Szücs A, et al. Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer’s disease. Cell Metab. 2022;34:1248–63.e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. de Sousa RT, Streck EL, Zanetti MV, Ferreira GK, Diniz BS, Brunoni AR, et al. Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology (Berl). 2015;232:245–50.

    Article  PubMed  Google Scholar 

  52. Machado-Vieira R, Zanetti MV, Otaduy MC, De Sousa RT, Soeiro-de-Souza MG, Costa AC, et al. Increased brain lactate during depressive episodes and reversal effects by lithium monotherapy in drug-naive bipolar disorder: A 3-T 1H-MRS study. J Clin Psychopharmacol. 2017;37:4045.

    Article  Google Scholar 

  53. Meng F, Wang J, Wang L, Zou W. Glucose metabolism impairment in major depressive disorder. Brain Res Bull. 2025;221:111191.

    Article  CAS  PubMed  Google Scholar 

  54. Herculano-Houzel S, Rothman DL. From a demand-based to a SupplyLimited framework of brain metabolism. Front Integr Neurosci. 2022;16:818685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Matute C, Verkhratsky A. Brain myelin as a deficient energy source in aging and disease. Trends Endocrinol Metab. 2025;36:781–4.

    Article  CAS  PubMed  Google Scholar 

  56. Ramos-Cabrer P, Cabrera-Zubizarreta A, Padro D, Matute-González M, Rodríguez-Antigüedad A, Matute C. Reversible reduction in brain myelin content upon marathon running. Nat Metab. 2025;7:697–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Nave KA, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503–33.

    Article  CAS  PubMed  Google Scholar 

  58. Nave KA. Myelination and the trophic support of long axons. Nat Rev Neurosci. 2010;11:275–83.

    Article  CAS  PubMed  Google Scholar 

  59. Du F, Cooper AJ, Thida T, Shinn AK, Cohen BM, Ongür D. Myelin and axon abnormalities in schizophrenia measured with magnetic resonance imaging techniques. Biol Psychiatry. 2013;74:4517.

    Article  Google Scholar 

  60. Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, et al. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. Mol Psychiatry. 2018;23:1261–9.

    Article  CAS  PubMed  Google Scholar 

  61. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798–805.

    Article  CAS  PubMed  Google Scholar 

  62. López-Muguruza E, Peiró-Moreno C, Ruiz A, Matute C. Oligodendrocyte and myelin pathophysiology in multiple sclerosis. Adv Neurobiol. 2025;43:317–61.

    Article  PubMed  Google Scholar 

  63. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280:1610–3.

    Article  CAS  PubMed  Google Scholar 

  64. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and longterm axonal integrity. Nature. 2012;485:517–21.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Theriault JE, Shaffer C, Dienel GA, Sander CY, Hooker JM, Dickerson BC, et al. A functional account of stimulation-based aerobic glycolysis and its role in interpreting BOLD signal intensity increases in neuroimaging experiments. Neurosci Biobehav Rev. 2023;153:105373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Chomiak T, Hu B. What is the optimal value of the g-ratio for myelinated fibers in the rat CNS? A theoretical approach. PLoS ONE. 2009;4:e7754.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Uranova NA, Vikhreva OV, Rachmanova VI, Orlovskaya DD. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study. Schizophr Res Treatment. 2011;2011:325789.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Vostrikov V, Orlovskaya D, Uranova N. Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World J Biol Psychiatry. 2008;9:34–42.

    Article  PubMed  Google Scholar 

  69. Vostrikov VM, Uranova NA, Rakhmanova VI, Orlovskaia DD. Lowered oligodendroglial cell density in the prefrontal cortex in schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104:47–51.

    CAS  PubMed  Google Scholar 

  70. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res. 2004;67:269–75.

    Article  PubMed  Google Scholar 

  71. Howes OD, Cummings C, Chapman GE, Shatalina E. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023;48:151–67.

    Article  PubMed  Google Scholar 

  72. Bertolero MA, Yeo BT, D’Esposito M. The modular and integrative functional architecture of the human brain. Proc Natl Acad Sci USA. 2015;112:E6798–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Chen Y, Lin Q, Liao X, Zhou C, He Y. Association of aerobic glycolysis with the structural connectome reveals a benefit-risk balancing mechanism in the human brain. Proc Natl Acad Sci USA. 2021;118:e2013232118.

    Article  CAS  PubMed  Google Scholar 

  74. Baker JT, Holmes AJ, Masters GA, Yeo BT, Krienen F, Buckner RL. Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder. JAMA Psychiatry. 2014;71:109–18.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Segarra-Mondejar M, Casellas-Díaz S, Ramiro-Pareta M, Müller-Sánchez C, Martorell-Riera A, Hermelo I, et al. Synaptic activity-induced glycolysis facilitates membrane lipid provision and neurite outgrowth. EMBO J. 2018;37:e97368.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Chen K, Cheng P, Wang H, Gao S, Li X, Deng Z, et al. Lactate transport facilitates neurite outgrowth. Biosci Rep. 2018;38:BSR20180157.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Margineanu MB, Mahmood H, Fiumelli H, Magistretti PJ. L-Lactate regulates the expression of synaptic plasticity and neuroprotection genes in cortical neurons: A transcriptome analysis. Front Mol Neurosci. 2018;11:375.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Bolanos JP, Almeida A. The pentose-phosphate pathway in neuronal survival against nitrosative stress. IUBMB Life. 2010;62:14–8.

    Article  CAS  PubMed  Google Scholar 

  79. Freund TF, Katona I. Perisomatic inhibition. Neuron. 2007;56:33–42.

    Article  CAS  PubMed  Google Scholar 

  80. Zhang K, Liao P, Wen J, Hu Z. Synaptic plasticity in schizophrenia pathophysiology. IBRO Neurosci Rep. 2023;14:244–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Forsyth JK, Lewis DA. Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: An integrative model for diverse clinical features. Trends Cogn Sci. 2017;21:760778.

    Article  Google Scholar 

Download references

Funding

F.D. and D.O. received research funding from the National Institutes of Health (R01MH114982 [Du/Ongur], P50MH115846 [Ongur], R01AG066670 [Du/Forester], and R01MH135093 [Du/Ongur]). V.-A.C. received funding from the Baszucki Group.

Author information

Authors and Affiliations

  1. McLean Hospital, Harvard Medical School, Belmont, MA, USA

    Onur Memetoglu, Virginie-Anne Chouinard, Fei Du & Dost Ongur

  2. Washington University School of Medicine, St. Louis, MO, USA

    Manu S. Goyal

Authors
  1. Onur Memetoglu
    View author publications

    Search author on:PubMed Google Scholar

  2. Manu S. Goyal
    View author publications

    Search author on:PubMed Google Scholar

  3. Virginie-Anne Chouinard
    View author publications

    Search author on:PubMed Google Scholar

  4. Fei Du
    View author publications

    Search author on:PubMed Google Scholar

  5. Dost Ongur
    View author publications

    Search author on:PubMed Google Scholar

Contributions

OM, MSG, V-AC, FD, and DO contributed to the conception and intellectual development of the manuscript and drafted or revised the work for intellectual content. OM, MSG, and DO prepared the figures. All authors approved the final version and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Dost Ongur.

Ethics declarations

Previous presentation

This work has not been presented at a scientific meeting.

Prior editorial communication

We have not had prior discussions with a Molecular Psychiatry editor regarding this work.

Related manuscripts

This manuscript is original, not published previously, and not under consideration elsewhere.

Use of AI-assisted technologies

This manuscript was prepared with the assistance of OpenAI’s ChatGPT for language refinement and formatting suggestions. All intellectual content, analyses, and conclusions are solely those of the authors.

Authorship and disclosures

All listed authors have made significant intellectual contributions to the conception, writing, and revision of this Perspective. All authors have reviewed and approved the final version.

Competing interests

D.O. has received honoraria from Rapport Therapeutics and Boehringer-Ingelheim. All other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Memetoglu, O., Goyal, M.S., Chouinard, VA. et al. Aerobic glycolysis in Schizophrenia: Developmental rescue or energetic breakdown?. Mol Psychiatry (2026). https://doi.org/10.1038/s41380-026-03460-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41380-026-03460-3

Search

Advanced search

Quick links